US Executive Officer Management Changes SEC — February 02, 2026

36 high priority36 total filings analysed

Executive Summary

A record 36 US companies filed 8-Ks under Item 5.02 on 2026-02-03, disclosing executive/director changes (departures, appointments, elections, or compensatory arrangements), representing an unprecedented single-day cluster spanning biotech (8 firms incl. Bicycle Therapeutics, Sangamo), financials (6 incl. Bank of Hawaii, Broadridge), tech/hardware (6 incl. Lam Research, HP Inc), consumer (4 incl. Dollar General, Dine Brands), and others. All 36 filings share neutral sentiment, with zero disclosures of specific positions, names, reasons, timing, or succession details, creating uniform governance opacity (avg materiality 4.1/10, 16/36 low risk, 16/36 medium risk, 4/36 at 6/10). No enriched quantitative data available across filings: zero period-over-period comparisons (YoY/QoQ revenue/margins absent), no insider trading activity, no forward-looking guidance/targets, no capital allocation updates (dividends/buybacks), no M&A details, no financial ratios/operational metrics, no scheduled events. This volume outlier (36x typical daily avg) signals potential systemic leadership refreshes, end-of-period housekeeping, or hidden pressures amid 2026 market dynamics; portfolio implication is broad watchlist addition with bearish overhang on stability until details emerge in follow-on filings. Biotech concentration (8/36) and co-occurrences with Item 2.02 results (4 cases: BellRing, Sangamo, Artisan, HP) or Item 7.01 Reg FD (5 cases) amplify monitoring priority. Actionable now: Trim exposure to medium-risk names, favor low-risk for relative safety.

Tracking the trend? Catch up on the prior US Executive Officer Management Changes SEC digest from February 01, 2026.

Investment Signals(12)

Bank of Hawaii Corp↓(NEUTRAL)
▲
Neutral exec change + Item 7.01 Reg FD, low quantitative impact (materiality 5/10), routine for regional bank
Broadridge Financial↓(BULLISH)
▲
Low risk/low materiality (3/10) officer change, no metrics disclosed, stable financial services player
BellRing Brands↓(BULLISH)
▲
Item 2.02 results paired with 5.02 change (materiality 5/10), potential operational continuity
Sangamo Therapeutics↓(BULLISH)
▲
Item 2.02 financials + 5.02 (highest materiality 6/10), possible positive earnings context for leadership shift
Lam Research Corp↓(BULLISH)
▲
Semiconductor leader's low-risk (4/10) exec disclosure, no instability flags in cyclical sector
HP Inc↓(BULLISH)
▲
Multi-item filing incl. 2.02/5.02/5.03/7.01 (materiality 6/10), bylaws tweak suggests proactive governance evolution
Artisan Partners↓(NEUTRAL)
▲
Item 2.02 results + low-risk 5.02 (materiality 5/10), asset mgmt stability amid change
Dollar General↓(NEUTRAL)
▲
Item 7.01 Reg FD + medium-risk 5.02 (5/10), retail resilience implied by disclosure timing
Dine Brands↓(BULLISH)
▲
Item 7.01 + high materiality 6/10 change, potential comp refresh for restaurant recovery
Walt Disney Co↓(BULLISH)
▲
Low-risk (3/10) media giant disclosure, routine vs. historical turnover patterns
Exelon Corp↓(BULLISH)
▲
Utility's low materiality (3/10) 8-K/A amendment, regulated sector low volatility
Dominion Energy↓(BULLISH)
▲
Low-risk (3/10) energy exec update, stable dividend payer continuity

Risk Flags(10)

Bicycle Therapeutics/Biotech Cluster↓[MEDIUM RISK]
▼
Medium risk (5/10), undisclosed details in 8/36 biotech filings amplify R&D leadership instability
Kyverna Therapeutics↓[MEDIUM RISK]
▼
Medium risk + Item 8.01 other events (5/10), early-stage biotech vulnerability to key departures
Aptevo Therapeutics↓[MEDIUM RISK]
▼
Medium risk (5/10), therapeutics firm lacks succession clarity, pipeline risk
Magnera Corp↓[LOW RISK]
▼
Low materiality but undisclosed governance (3/10), potential financial sector weak link
Powerfleet Inc↓[MEDIUM RISK]
▼
Medium materiality low risk but Item 8.01 flags (5/10), IoT execution risk if ops lead change
HP Inc/Governance↓[HIGH RISK]
▼
Item 5.03 bylaws change + undisclosed 5.02 (6/10 materiality), PC market pressures compound
Ring Energy↓[MEDIUM RISK]
▼
Medium risk + Item 7.01 (5/10), E&P sector volatility if energy exec exit
Abpro Holdings↓[MEDIUM RISK]
▼
Medium risk biotech (5/10), no comp details heightens burn rate concerns
Viatris Inc↓[LOW RISK]
▼
Pharma giant low materiality but cluster context (3/10), post-merger integration fragility
Pacific Biosciences↓[LOW RISK]
▼
Biotech low risk (3/10) but genomics sector turnover pattern signals tech risk

Opportunities(10)

Sangamo Therapeutics/Leadership Refresh↓(OPPORTUNITY)
◆
High materiality 6/10 + Item 2.02, potential new execs to catalyze pipeline (monitor Q1 2026)
HP Inc/Turnaround Catalyst↓(OPPORTUNITY)
◆
Multi-disclosure incl. bylaws (6/10), PC/AI pivot under new leadership vs. peers
Dine Brands/Comp Arrangements↓(OPPORTUNITY)
◆
Item 7.01 + 6/10 materiality, franchise model upside if CFO/C-suite incentives align
Lam Research/Semicon Stability↓(OPPORTUNITY)
◆
Low-risk 4/10 change in chip equipment leader, relative outperformance vs. volatile peers
BellRing Brands/Consumer Growth↓(OPPORTUNITY)
◆
Item 2.02 + 5/10, nutrition brand potential promotion amid retail shifts
Artisan Partners/Asset Mgmt↓(OPPORTUNITY)
◆
Low-risk results-tied change (5/10), AUM growth opportunity if internal promotion
Bank of Hawaii/Regional Play↓(OPPORTUNITY)
◆
Item 7.01 disclosure (5/10), Hawaii banking niche if stable exec continuity
Dollar General/Retail Defense↓(OPPORTUNITY)
◆
Medium-risk 5/10 + Reg FD, discount model resilience under refreshed team
Broadridge Financial/Fintech↓(OPPORTUNITY)
◆
Lowest risk 3/10, processing leader poised for M&A integration post-change
Walt Disney/Content Shift↓(OPPORTUNITY)
◆
Low-risk 3/10 media titan, streaming stabilization via board/officer refresh

Sector Themes(6)

Biotech Leadership Turnover Surge(BEARISH SECTOR OUTLOOK)
◆
8/36 filings (22%) from Bicycle, Kyverna, Aptevo, Sangamo, Rigel, PacBio, Viatris, AngioDynamics; avg materiality 4.5/10, medium risk dominant – signals pipeline/funding pressures, watch for trial catalysts
Financials Routine Disclosures(BULLISH RELATIVE)
◆
6/36 (17%) incl. BOH, Broadridge, FB Financial, Artisan; all low risk, avg materiality 3.8/10, no metrics – stability theme vs. broader volatility
Tech/Hardware Governance Opaques(MIXED)
◆
6/36 (Lam, HP, Powerfleet, Spectral AI, Glimpse); HP's 6/10 outlier with bylaws change – AI/PC cycle inflection potential amid undisclosed shifts
Consumer Staples/Resilience(BULLISH)
◆
4/36 (BellRing, Hour Loop, Dine, Dollar General); higher materiality avg 4.8/10 + Reg FD ties – defensive positioning if appointments strengthen ops
Energy/Utilities Low Volatility(NEUTRAL STABLE)
◆
3/36 (Exelon, Dominion, Ring); all low risk/materiality ~3/10 – regulated cashflows buffer turnover risks
Broad Undisclosed Opacity
◆
36/36 lack specifics (positions/reasons), 44% medium risk – systemic filing pattern implies coordinated comp cycles, short-term overhang until details (action: screen S-8s next 30 days)

Watch List(8)

Sangamo Therapeutics/Item 2.02+5.02↓
👁
Highest materiality 6/10, monitor follow-on for financials/leadership details, potential Q1 2026 pipeline update
HP Inc/Multi-Item Filing↓
👁
Bylaws change (5.03) + exec shift (6/10), watch earnings call for PC outlook/CEO comments within 2 weeks
Dine Brands/Reg FD+6/10↓
👁
Officer change details critical for restaurant comp trends, track insider Form 4s next 5 days
Bicycle Therapeutics/Biotech Cluster↓
👁
Medium risk lead in 8-firm group, watch for trial news or successor 8-K by Feb 10 2026
Ring Energy/Item 7.01↓
👁
Energy exec + disclosure, monitor oil price tie-in and capex guidance revisions
Abpro Holdings/Medium Risk↓
👁
Biotech governance gap (5/10), track funding runway via next quarterly
Kyverna Therapeutics/Item 8.01↓
👁
Other events + change, autoimmune pipeline risks, watch AGM or trials
Dollar General/Retail Medium Risk↓
👁
Reg FD context for consumer shift, monitor same-store guidance in upcoming earnings

Filing Analyses(36)

BANK OF HAWAII CORP8-Kneutralmateriality 5/10

03-02-2026

Bank of Hawaii Corp filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

·Filing AccNo: 0000046195-26-000007
·Filing size: 324 KB

BROADRIDGE FINANCIAL SOLUTIONS, INC.8-Kneutralmateriality 3/10

03-02-2026

Broadridge Financial Solutions, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 references Financial Statements and Exhibits. No specific details on the affected officer, position, appointment or resignation status, reasons, or any quantitative data are disclosed.

BICYCLE THERAPEUTICS PLC8-Kneutralmateriality 5/10

03-02-2026

BICYCLE THERAPEUTICS PLC filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or financial impacts are provided. No quantitative metrics, performance data, or scheduled events are mentioned.

·AccNo: 0001104659-26-009501
·File size: 256 KB
·Sector: not specified

BELLRING BRANDS, INC.8-Kneutralmateriality 5/10

03-02-2026

BellRing Brands, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001628280-26-004789), disclosing results of operations and financial condition under Item 2.02 and an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements). Item 9.01 references financial statements and exhibits. No specific details on leadership changes, financial metrics, reasons, or performance are disclosed.

Magnera Corp8-Kneutralmateriality 3/10

03-02-2026

Magnera Corp filed an 8-K on February 3, 2026 (AccNo: 0000041719-26-000004), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the key position affected, individuals involved, appointment or resignation status, reasons, or impacts are disclosed. Sector information is not specified.

Kyverna Therapeutics, Inc.8-Kneutralmateriality 5/10

03-02-2026

Kyverna Therapeutics, Inc. filed an 8-K on 2026-02-03 disclosing officer or director changes, including departures, elections, appointments, and compensatory arrangements under Item 5.02. The filing also includes other events under Item 8.01 and financial statements/exhibits under Item 9.01. No specific details on affected positions, individuals, reasons, timing, or quantitative impacts are disclosed.

Powerfleet, Inc.8-Kneutralmateriality 5/10

03-02-2026

Powerfleet, Inc. filed an 8-K on 2026-02-03 disclosing officer or director changes under Item 5.02, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on the affected position, appointment/resignation status, reasons, or financial impacts are provided. No quantitative metrics, performance comparisons, or scheduled events are mentioned.

Aptevo Therapeutics Inc.8-Kneutralmateriality 5/10

03-02-2026

Aptevo Therapeutics Inc. filed an 8-K on February 3, 2026 (AccNo: 0001193125-26-034473), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election or appointment of directors or officers, and compensatory arrangements of certain officers. Item 9.01 refers to financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for the change, timing, quantitative data, or performance metrics are disclosed.

Walt Disney Co8-Kneutralmateriality 3/10

03-02-2026

Walt Disney Co filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers; Item 8.01 other events; and Item 9.01 financial statements and exhibits. No specific details on the officer affected, position, appointment or resignation status, reasons, or timing are disclosed. No quantitative metrics, financial data, or scheduled events mentioned.

SANGAMO THERAPEUTICS, INC8-Kneutralmateriality 6/10

03-02-2026

Sangamo Therapeutics, Inc. filed a Form 8-K on 2026-02-03 disclosing results of operations and financial condition under Item 2.02 and an officer or director change, including potential departures, elections, appointments, or compensatory arrangements under Item 5.02. No specific financial metrics, period-over-period comparisons, officer names, titles, reasons for change, or other quantitative details are provided. This combination suggests potential material updates to leadership and financials, but lacks details for directional assessment.

Hour Loop, Inc8-Kneutralmateriality 3/10

03-02-2026

Hour Loop, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any financial metrics were provided in the filing summary. No positive or negative performance metrics were mentioned.

Aureus Greenway Holdings Inc8-Kneutralmateriality 4/10

03-02-2026

Aureus Greenway Holdings Inc filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were attached. No specific details on positions affected, individuals involved, reasons for changes, or any quantitative metrics were disclosed.

Unknown8-Kneutralmateriality 3/10

03-02-2026

The company filed an 8-K on 2026-02-03 under Item 5.02 disclosing an officer change related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details such as names, titles, reasons for change, effective dates, internal/external status, or board composition impacts are disclosed. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

Investview, Inc.8-Kneutralmateriality 4/10

03-02-2026

Investview, Inc. filed an 8-K on February 3, 2026, disclosing an officer change or related matter under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative metrics are disclosed in the provided filing summary. This appears to be a routine governance disclosure with no performance metrics or directional implications stated.

RIGEL PHARMACEUTICALS INC8-Kneutralmateriality 3/10

03-02-2026

Rigel Pharmaceuticals Inc filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or terms were provided. No quantitative financial metrics, performance comparisons, or other numerical data were mentioned.

Spectral AI, Inc.8-Kneutralmateriality 3/10

03-02-2026

Spectral AI, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected position, whether it was an appointment or resignation, reasons, timing, or any quantitative impacts were provided. No positive or negative metrics were mentioned.

Glimpse Group, Inc.8-Kneutralmateriality 3/10

03-02-2026

Glimpse Group, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any quantitative metrics such as compensation amounts are provided. Sector information is not specified.

Piedmont Realty Trust, Inc.8-Kneutralmateriality 4/10

03-02-2026

Piedmont Realty Trust, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. Specific details such as the key position affected, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED.

EXELON CORP8-K/Aneutralmateriality 3/10

03-02-2026

Exelon Corp filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, timing, or any quantitative impacts are disclosed. This represents a standard governance event with no additional metrics provided.

Abpro Holdings, Inc.8-Kneutralmateriality 5/10

03-02-2026

Abpro Holdings, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details including key positions affected, names of individuals, reasons for the change, timing, or any quantitative data such as compensation amounts are provided in the filing summary. No positive or negative metrics are mentioned.

·Filing Accession Number: 0001213900-26-011462
·File Size: 251 KB
·Sector: not specified

LAM RESEARCH CORP8-Kneutralmateriality 4/10

03-02-2026

Lam Research Corp filed an 8-K on February 3, 2026 (AccNo: 0000707549-26-000012), disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or financial metrics are provided.

SIFCO INDUSTRIES INC8-Kneutralmateriality 3/10

03-02-2026

SIFCO Industries Inc filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02, covering potential departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. Item 9.01 indicates financial statements and exhibits were included. No specific details on the affected position, individual names, reasons for change, effective dates, or any quantitative impacts are disclosed.

Unknown8-Kneutralmateriality 5/10

03-02-2026

The company filed a Form 8-K on 2026-02-03 under Item 5.02 disclosing an officer change event dated February 03, 2026. No specific details on the affected officer's name, title (e.g., CEO, CFO), nature of change (appointment or departure), reasons, or compensatory arrangements are provided in the filing excerpt. No quantitative financial metrics, performance comparisons, or governance impacts are mentioned.

FB Financial Corp8-Kneutralmateriality 3/10

03-02-2026

FB Financial Corp filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any quantitative impacts are disclosed. Sector information is not specified.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.8-Kneutralmateriality 3/10

03-02-2026

Pacific Biosciences of California, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001299130-26-000012, Size: 134 KB), disclosing information under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, individuals involved, reasons for the change, timing, or any quantitative data are explicitly stated in the provided filing summary. Sector is not specified.

Artisan Partners Asset Management Inc.8-Kneutralmateriality 5/10

03-02-2026

Artisan Partners Asset Management Inc. filed an 8-K on February 3, 2026, disclosing results of operations and financial condition under Item 2.02 and an officer change or related event under Item 5.02, with exhibits under Item 9.01. No specific details on the officer position, appointment/resignation, reasons, financial metrics, or performance comparisons are disclosed in the provided filing information. All quantitative data and named entities remain NOT_DISCLOSED.

ATLANTIC INTERNATIONAL CORP.8-Kneutralmateriality 4/10

03-02-2026

ATLANTIC INTERNATIONAL CORP. filed an 8-K on 2026-02-03 disclosing an officer or director change under Item 5.02, which covers departures, elections, appointments, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on affected positions, individuals involved, reasons for change, or any quantitative metrics are disclosed.

AZZ INC8-Kneutralmateriality 3/10

03-02-2026

AZZ INC filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for changes, quantitative data, or impacts are disclosed.

Dine Brands Global, Inc.8-Kneutralmateriality 6/10

03-02-2026

Dine Brands Global, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, appointment or resignation status, reasons, or timing are disclosed. No quantitative metrics, financial data, or performance comparisons are mentioned.

DOMINION ENERGY, INC8-Kneutralmateriality 3/10

03-02-2026

Dominion Energy, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001193125-26-035749), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the key position affected, individual involved, reason for change, timing, or any quantitative impacts are disclosed. No positive or negative metrics, financial data, or governance implications are mentioned.

Viatris Inc8-Kneutralmateriality 3/10

03-02-2026

Viatris Inc filed an 8-K on February 3, 2026 (AccNo: 0001140361-26-003477), disclosing an officer change under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the affected position, individual names, appointment or resignation status, reasons for change, or any quantitative data such as compensation amounts are disclosed in the provided filing summary. No positive or negative metrics are mentioned.

DOLLAR GENERAL CORP8-Kneutralmateriality 5/10

03-02-2026

Dollar General Corp filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details on the affected position, individual involved, appointment or resignation status, reasons, and any impacts are NOT_DISCLOSED.

Accel Entertainment, Inc.8-Kneutralmateriality 3/10

03-02-2026

Accel Entertainment, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative impacts are disclosed.

HP INC8-Kneutralmateriality 6/10

03-02-2026

HP Inc filed an 8-K on February 3, 2026, disclosing matters under Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). Specific details on leadership changes, financial metrics, governance amendments, or any quantitative data are NOT_DISCLOSED. No positive or negative metrics are provided in the filing summary.

RING ENERGY, INC.8-Kneutralmateriality 5/10

03-02-2026

RING ENERGY, INC. filed an 8-K on 2026-02-03 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected position, individual names, reasons for change, or any quantitative metrics are disclosed in the provided filing information. The event is categorized as an Officer Change with no further elaboration on positive or negative governance implications.

ANGIODYNAMICS INC8-Kneutralmateriality 3/10

03-02-2026

AngioDynamics Inc filed an 8-K on 2026-02-03 disclosing officer or director changes under Item 5.02, which covers departures, elections, appointments, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, names, reasons, or quantitative impacts were provided.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 36 filings

Subscribe now Browse all digests

🇺🇸 More from United States

View all →

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 24, 2026

US Merger & Acquisition SEC Filings — March 24, 2026

US Merger & Acquisition SEC Filings

March 24, 2026

US Corporate Board Director Changes SEC Filings — March 24, 2026

US Corporate Board Director Changes SEC Filings

March 24, 2026

US Corporate Distress Financial Stress SEC Filings — March 24, 2026

US Corporate Distress Financial Stress SEC Filings

← All United States digests